Temoporfin-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: A multicenter study

Head and Neck

Volumn 32, Issue 12, 2010, Pages 1597-1604

  Tan, Ing Bing ^a   Dolivet, Gilles ^b   Ceruse, Philippe ^c   Poorten, Vincent Vander ^d   Roest, Gerda ^e   Rauschning, Winrich ^f  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b CENTRE ALEXIS VAUTRIN   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e SYNEOS HEALTH   (United States)

^f Biolitec Pharma Ltd   (Ireland)

Author keywords

Foscan; head and neck tumors; photodynamic therapy; squamous cell carcinoma of the head and neck; temoporfin

Indexed keywords

TEMOPORFIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; PAIN; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MESOPORPHYRINS; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 78649651784     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21368     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. GLOBOCAN 2002 downloadable from
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P,. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
3. Boring CC, Squires TS, Tong T, Montgomery S,. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7-26.
4. Galante E, Gallus G, Chiesa F, Bono A, Bettoni I, Molinari R,. Growth rate of head and neck tumors. Eur J Cancer Clin Oncol 1982; 18: 707-712.
5. Steel GG,. The growth rate of tumors. In:, Steel G, editor. Basic clinical radiobiology (2nd ed). London: Arnold; 1997. pp 9-13.
6. Kramer S, Marcial VA, Pajak TF, MacLean CJ, Davis LW,. Prognostic factors for loco/regional control and metastasis and the impact on survival. Int J Radiat Oncol Biol Phys 1986; 12: 573-578.
7. Carvalho AL, Salvajoli JV, Kowalski LP,. A comparison of radiotherapy or radiochemotherapy with symptomatic treatment alone in patients with advanced head and neck carcinomas. Eur Arch Otorhinolaryngol 2000; 257: 164-167.
8. Schwartz GJ, Mehta RH, Wenig BL, Shaligram C, Portugal LG,. Salvage treatment for recurrent squamous cell carcinoma of the oral cavity. Head Neck 2000; 22: 34-41.
9. Jovanovic A, van der Tol IG, Schulten EA, et al. Risk of multiple primary tumors following oral squamous cell carcinoma. Int J Cancer 1994; 56: 320-323.
10. Forastiere A, Koch W, Trotti A, Sidransky D,. Head and neck cancer. N Engl J Med 2001; 345: 1890-1900.
11. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-1251.
12. Sulman EP, Schwartz DL, Le TT, et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2009; 73: 399-409.
13. Wong SJ, Machtay M, Li Y,. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? J Clin Oncol 2006; 24: 2653-2658.
14. Kasperts N, Slotman B, Leemans CR, Langendijk JA,. A review on re-irradiation for recurrent and second primary head and neck cancer. Oral Oncol 2005; 41: 225-243.
15. Bensadoun RJ, Magne N, Marcy PY, Demard F,. Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. Eur Arch Otorhinolaryngol 2001; 258: 481-487.
16. Dougherty TJ, Marcus SL,. Photodynamic therapy. Eur J Cancer 1992; 28A: 1734-1742.
17. Dilkes MG, Alusi G, Djaezeri BJ,. The treatment of head and neck cancer with photodynamic therapy: clinical experience. Rev Contemp Pharmacother 1999; 10: 47-57.
18. Fisher AM, Murphree AL, Gomer CJ,. Clinical and preclinical photodynamic therapy. Lasers Surg Med 1995; 17: 2-31.
19. D'Cruz AK, Robinson MH, Biel MA,. mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 Patients. Head Neck 2004; 26: 232-240.
20. Tan IB, Oppelaar H, Ruevekamp MC, Veenhuizen RB, Timmers A, Stewart FA,. The importance of in situ light dosimetry for photodynamic therapy of oral cavity tumors. Head Neck 1999; 21: 434-441.
21. World Health Organisation. WHO handbook for reporting results of cancer. Geneva, Switzerland: WHO Offset Publications; 1980.
22. Bonnett R,. Photodynamic therapy in historical perspective. Rev Contemp Pharmacother 1999; 10: 1-17.
23. Byar DP, Schoenfeld DA, Green SB, et al. Design considerations for AIDS trials. N Engl J Med 1990; 323: 1343-1348.